Biodesix, Inc. (BDSX)

1.2771 +0.0271 (+2.20%) As of 10:32AM EDT. Market open.

Biodesix, Inc.

919 West Dillon Road
Louisville, CO 80027
United States
303 417 0500
https://www.biodesix.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 217

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Scott Hutton	President, CEO & Director	614.92k	N/A	1972
Ms. Robin Harper Cowie	CFO, Secretary & Treasurer	390.3k	N/A	1980
Mr. Kieran O'Kane	Chief Commercial Officer	392.61k	N/A	1977
Dr. Heinrich Röder	Founder & CTO	N/A	N/A	N/A
Mr. Christopher Vazquez	VP, Controller & Chief Accounting Officer	N/A	N/A	N/A
Mr. Mark DeBlock	Vice President of Sales	N/A	N/A	N/A
Mr. Robbie Lunt	Senior Director of Marketing	N/A	N/A	N/A
Ms. Jessica Olbricht	Senior Director of Human Resources	N/A	N/A	N/A
Dr. Gary Anthony Pestano Ph.D.	Chief Development Officer	N/A	N/A	1967
Ms. Bobbi Coffin	Chief Growth Officer	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Corporate governance

Biodesix, Inc.’s ISS governance QualityScore as of 29 April 2024 is 9. The pillar scores are Audit: 8; Board: 5; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.